Targeting the NLRP3 inflammasome in chronic inflammatory diseases: Current perspectives

Journal of Inflammation Research

Volumn 8, Issue , 2015, Pages 15-27

  Ozaki, Ema ^a   Campbell, Matthew ^a   Doyle, Sarah L ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

Caspase 1; Inflammasome; Interleukin 1; Interleukin 18; NLRP3; Therapeutics

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTIRHEUMATIC AGENT; BELNACASAN; CANAKINUMAB; CE 224535; CRYOPYRIN; GLIBENCLAMIDE; GSK 1070806; GSK 1482169; IBOCTADEKIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; PARTHENOLIDE; PRALNACASAN; PROTEIN INHIBITOR; RILONACEPT; UNCLASSIFIED DRUG;

ADVANCED CANCER; B CELL LYMPHOMA; CHRONIC INFLAMMATION; COMPLEX FORMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GAIN OF FUNCTION MUTATION; GOUT; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INHIBITION KINETICS; MOLECULAR RECOGNITION; MUCKLE WELLS SYNDROME; NLRP3 GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OLIGOMERIZATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATOR GENE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84923354387     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S51250     Document Type: Review

References (133)

1. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular plat­form triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417-426.
2. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011;11(3):213-220.
3. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6): 821-832.
4. Cridland JA, Curley EZ, Wykes MN, et al. The mammalian PYHIN gene family: phylogeny, evolution and expression. BMC Evol Biol. 2012;12:140.
5. Minkiewicz J, de Rivero Vaccari JP, Keane RW. Human astrocytes express a novel NLRP2 inflammasome. Glia. 2013;61(7):1113-1121.
6. Faustin B, Lartigue L, Bruey JM, et al. Reconstituted NALP1 inflam­masome reveals two-step mechanism of caspase-1 activation. Mol Cell. 2007;25(5):713-724.
7. Miao EA, Alpuche-Aranda CM, Dors M, et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol. 2006;7(6):569-575.
8. Franchi L, Amer A, Body-Malapel M, et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol. 2006;7(6):576-582.
9. Hornung V, Ablasser A, Charrel-Dennis M, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458(7237):514-518.
10. Grenier JM, Wang L, Manji GA, et al. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett. 2002;530(1-3):73-78.
11. Wang L, Manji GA, Grenier JM, et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J Biol Chem. 2002;277(33):29874-29880.
12. Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell. 2012;150(3):606-619.
13. Allen IC, Scull MA, Moore CB, et al. The NLRP3 inflammasome medi­ates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity. 2009;30(4):556-565.
14. Thomas PG, Dash P, Aldridge JR Jr, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity. 2009;30(4):566-575.
15. Gross O, Poeck H, Bscheider M, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature. 2009;459(7245):433-436.
16. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440(7081): 228-232.
17. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241.
18. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857-865.
19. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 2010;11(10): 897-904.
20. Doyle SL, Campbell M, Ozaki E, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med. 2012;18(5):791-798.
21. Kummer JA, Broekhuizen R, Everett H, et al. Inflammasome com­ponents NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem. 2007;55(5):443-452.
22. Duncan JA, Bergstralh DT, Wang Y, et al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci U S A. 2007;104(19):8041-8046.
23. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol. 2011;187(2): 613-617.
24. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regu­late NLRP3 inflammasome activation. J Biol Chem. 2012;287(43):36617-36622.
25. Lopez-Castejon G, Luheshi NM, Compan V, et al. Deubiquitinases regu­late the activity of caspase-1 and interleukin-1beta secretion via assem­bly of the inflammasome. J Biol Chem. 2013;288(4):2721-2733.
26. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intra­cellular potassium concentration. Cell Death Differ. 2007;14(9): 1583-1589.
27. Kanneganti TD, Lamkanfi M, Kim YG, et al. Pannexin-1-mediated rec­ognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity. 2007;26(4): 433-443.
28. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006;25(21):5071-5082.
29. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847-856.
30. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136-140.
31. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221-225.
32. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mito­chondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12(3):222-230.
33. Compan V, Baroja-Mazo A, Lopez-Castejon G, et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity. 2012;37(3):487-500.
34. Gong YN, Wang X, Wang J, et al. Chemical probing reveals insights into the signaling mechanism of inflammasome activation. Cell Res. 2010;20(12):1289-1305.
35. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254.
36. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-1361.
37. Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331(6016):456-461.
38. Mathews RJ, Robinson JI, Battellino M, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to sus­ceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis. 2014;73(6):1202-1210.
39. Vande Walle L, Van Opdenbosch N, Jacques P, et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature. 2014;512(7512):69-73.
40. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599-603.
41. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603-606.
42. Aguilera M, Darby T, Melgar S. The complex role of inflammasomes in the pathogenesis of inflammatory bowel diseases - lessons learned from experimental models. Cytokine Growth Factor Rev. April 18, 2014. [Epub ahead of print.]
43. Kanai T, Watanabe M, Okazawa A, et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn’s disease. Gastroenterology. 2001;121(4):875-888.
44. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32(3): 379-391.
45. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. Nat Genet. 2009;41(1):71-76.
46. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe? Immunity. 2010;32(3):300-302.
47. Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell. 2014;5(1):12-20.
48. Winter RN, Rhee JG, Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res. 2004;24(3a):1377-1386.
49. Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001;61(3):1227-1232.
50. Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflam­masome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207(5):1045-1056.
51. Dao T, Mehal WZ, Crispe IN. IL-18 augments perforin-dependent cyto­toxicity of liver NK-T cells. J Immunol. 1998;161(5):2217-2222.
52. Micallef MJ, Yoshida K, Kawai S, et al. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bear­ing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother. 1997;43(6):361-367.
53. Osaki T, Peron JM, Cai Q, et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol. 1998;160(4):1742-1749.
54. Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-de­pendent immunosuppression in cancer. Cancer Res. 2011;71(16):5393-5399.
55. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic dis­ease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2): 114-122.
56. Ozkurede VU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol. 2012;167(3):382-390.
57. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007;14(1):10-22.
58. Federici S, Caorsi R, Gattorno M. The autoinflammatory diseases. Swiss Med Wkly. 2012;142:w13602.
59. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype includ­ing recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 2002;46(9):2445-2452.
60. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syn­drome by interleukin-1 receptor antagonist. Lancet. 2004;364(9447): 1779-1785.
61. Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258-267.
62. Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra. J Pediatr. 2010;157(2):310-315. e311.
63. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. A 2006;355(6):581-592.
64. Tan MS, Yu JT, Jiang T, Zhu XC, Tan L. The NLRP3 inflammasome in Alzheimer’s disease. Mol Neurobiol. 2013;48(3):875-882.
65. Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol. 2013;147(3):242-275.
66. Zhang H. Anti-IL-1beta therapies. Recent Pat DNA Gene Seq. 2011;5(2):126-135.
67. Kone-Paut I, Galeotti C. Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2014;10(1):7-18.
68. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-652.
69. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115(8):2047-2058.
70. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187(1):61-70.
71. Marchetti C, Chojnacki J, Toldo S, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63(4):316-322.
72. Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E. Ethnopharmacology of Mexican asteraceae (Compositae). Annu Rev Pharmacol Toxicol. 1998;38:539-565.
73. Juliana C, Fernandes-Alnemri T, Wu J, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285(13):9792-9802.
74. Coll RC, O’Neill LA. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS One. 2011;6(12):e29539.
75. Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71(10):1630-1635.
76. Stock TC, Bloom BJ, Wei N, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheuma­toid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012;39(4):720-727.
77. Ali Z, Laurijssens B, Ostenfeld T, et al. Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modula­tor GSK1482160 in healthy human subjects. Br J Clin Pharmacol. 2013;75(1):197-207.
78. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs. 2011;20(7):897-915.
79. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
80. Neta R, Douches S, Oppenheim JJ. Interleukin 1 is a radioprotector. J Immunol. 1986;136(7):2483-2485.
81. Hancock SL, Chung RT, Cox RS, Kallman RF. Interleukin 1 beta ini­tially sensitizes and subsequently protects murine intestinal stem cells exposed to photon radiation. Cancer Res. 1991;51(9):2280-2285.
82. Bergmann M, Barnes PJ, Newton R. Molecular regulation of granu­locyte macrophage colony-stimulating factor in human lung epithelial cells by interleukin (IL)-1beta, IL-4, and IL-13 involves both transcrip­tional and post-transcriptional mechanisms. Am J Respir Cell Mol Biol. 2000;22(5):582-589.
83. Bagby GC Jr. Interleukin-1 and hematopoiesis. Blood Rev. 1989;3(3): 152-161.
84. Crown J, Jakubowski A, Gabrilove J. Interleukin-1: biological effects in human hematopoiesis. Leuk Lymphoma. 1993;9(6):433-440.
85. Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppres­sive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood. 1991;78(6):1420-1427.
86. Nemunaitis J, Appelbaum FR, Lilleby K, et al. Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood. 1994;83(12):3473-3479.
87. Kitamura K, Takahashi T, Yamaguchi T, et al. Immunochemical characterization of the antigen recognized by the murine monoclonal antibody A7 against human colorectal cancer. Tohoku J Exp Med. 1989;157(2):83-93.
88. Puren AJ, Fantuzzi G, Dinarello CA. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A. 1999;96(5):2256-2261.
89. Netea MG, Joosten LA, Lewis E, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med. 2006;12(6):650-656.
90. Gatti S, Beck J, Fantuzzi G, Bartfai T, Dinarello CA. Effect of inter­leukin-18 on mouse core body temperature. Am J Physiol Regul Integr Comp Physiol. 2002;282(3):R702-R709.
91. Robertson MJ, Kirkwood JM, Logan TF, et al. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008;14(11):3462-3469.
92. Simpkins F, Flores A, Chu C, et al. Chemoimmunotherapy using PEGylated liposomal dDoxorubicin and interleukin-18 in recurrent ovarian cancer: a pphase I dose-escalation study. Cancer Immunol Res. 2013;1(3):168-178.
93. Tarhini AA, Millward M, Mainwaring P, et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009;115(4):859-868.
94. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289.
95. Robertson MJ, Mier JW, Logan T, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infu­sion to patients with advanced cancer. Clin Cancer Res. 2006;12(14 Pt 1):4265-4273.
96. Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis. 2011;17(6):1359-1372.
97. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145(5): 745-757.
98. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13(7):851-856.
99. Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity. 2010;32(3):367-378.
100. Tarallo V, Hirano Y, Gelfand BD, et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflam­masome and MyD88. Cell. 2012;149(4):847-859.
101. Tseng WA, Thein T, Kinnunen K, et al. NLRP3 inflammasome activa­tion in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013;54(1):110-120.
102. Marneros AG. NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration. Cell Rep. 2013;4(5):945-958.
103. Doyle SL, Ozaki E, Brennan K, et al. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration. Sci Transl Med. 2014;6(230):230ra244.
104. Shen J, Choy DF, Yoshida T, et al. Interleukin-18 has antipermeablity and antiangiogenic activities in the eye; reciprocal suppression with VEGF. J Cell Physiol. 2014;229(8):974-983.
105. Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage sus­ceptibility to anthrax lethal toxin. Nat Genet. 2006;38(2):240-244.
106. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319-325.
107. Kempster SL, Belteki G, Forhead AJ, et al. Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. Am J Physiol Gastrointest Liver Physiol. 2011;300(2):G253-G263.
108. Khare S, Dorfleutner A, Bryan NB, et al. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity. 2012;36(3):464-476.
109. Vladimer GI, Weng D, Paquette SW, et al. The NLRP12 inflammasome recognizes Yersinia pestis. Immunity. 2012;37(1):96-107.
110. Poyet JL, Srinivasula SM, Tnani M, Razmara M, Fernandes-Alnemri T, Alnemri ES. Identification of Ipaf, a human caspase-1-activating pro­tein related to Apaf-1. J Biol Chem. 2001;276(30):28309-28313.
111. Jesus AA, Silva CA, Segundo GR, et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare non-exon 3 and a novel CIAS1 missense mutation. J Clin Immunol. 2008;28(2):134-138.
112. Stojanov S, Weiss M, Lohse P, Belohradsky BH. A novel CIAS1 mutation and plasma/cerebrospinal fluid cytokine profile in a German patient with neonatal-onset multisystem inflammatory disease responsive to methotrexate therapy. Pediatrics. 2004;114(1): e124-e127.
113. Vlagopoulos T, Townley R, Villacorte G. Familial cold urticaria. Ann Allergy. 1975;34(6):366-369.
114. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301-305.
115. Aksentijevich I, D Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007;56(4):1273-1285.
116. Dodé C, Le Dû N, Cuisset L, et al. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet. 2002; 70(6):1498-1506.
117. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002;71(1):198-203.
118. Caroli F, Pontillo A, D’Osualdo A, et al. Clinical and genetic character­ization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford). 2007;46(3):473-478.
119. Mirault T, Launay D, Cuisset L, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum. 2006;54(5):1697-1700.
120. Boschan C, Witt O, Lohse P, Foeldvari I, Zappel H, Schweigerer L. Neo­natal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. Am J Med Genet A. 2006;140(8): 883-886.
121. Hoffman HM, Gregory SG, Mueller JL, et al. Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet. 2003;112(2):209-216.
122. Koike R, Kubota T, Hara Y, et al. A case of Muckle-Wells syndrome caused by a novel H312P mutation in NALP3 (cryopyrin). Mod Rheumatol. 2007;17(6):496-499.
123. Zeft A, Bohnsack JF. Cryopyrin-associated autoinflammatory syndrome: a new mutation. Ann Rheum Dis. 2007;66(6):843-844.
124. Shepard MK. Cold hypersensitivity. Birth Defects Orig Artic Ser. 1971;7(8):352.
125. Dalgic B, Egritas O, Sari S, Cuisset L. A variant Muckle-Wells syn­drome with a novel mutation in CIAS1 gene responding to anakinra. Pediatr Nephrol. 2007;22(9):1391-1394.
126. Arostegui JI, Aldea A, Modesto C, et al. Clinical and genetic het­erogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum. 2004;50(12):4045-4050.
127. Stack JH, Beaumont K, Larsen PD, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflam­matory syndrome patients. J Immunol. 2005;175(4):2630-2634.
128. Saito M, Nishikomori R, Kambe N, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood. 2008;111(4):2132-2141.
129. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflam­matory diseases. Arthritis Rheum. 2002;46(12):3340-3348.
130. Wanderer AA. An ‘allergy’ to cold. Hosp Pract. 1979;14(6): 136-137.
131. Matsubayashi T, Sugiura H, Arai T, Oh-Ishi T, Inamo Y. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Paediatr. 2006;95(2):246-249.
132. Ohnishi H, Teramoto T, Iwata H, et al. Characterization of NLRP3 variants in Japanese cryopyrin-associated periodic syndrome patients. J Clin Immunol. 2012;32(2):221-229.
133. Frenkel J, van Kempen MJ, Kuis W, van Amstel HK. Variant chronic infantile neurologic, cutaneous, articular syndrome due to a mutation within the leucine-rich repeat domain of CIAS1. Arthritis Rheum. 2004;50(8):2719-2720.